Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P35228

UPID:
NOS2_HUMAN

ALTERNATIVE NAMES:
Hepatocyte NOS; Inducible NO synthase; NOS type II; Peptidyl-cysteine S-nitrosylase NOS2

ALTERNATIVE UPACC:
P35228; A1L3U5; B7ZLY2; O60757; O94994; Q16263; Q16692; Q4TTS5; Q9UD42

BACKGROUND:
The inducible Nitric oxide synthase (NOS2) is crucial for producing nitric oxide, a versatile messenger molecule involved in numerous bodily functions. NOS2 exhibits tumoricidal and bactericidal properties in macrophages, has nitrosylase activity, and mediates the S-nitrosylation of cytoplasmic proteins, impacting various cellular processes. As part of the iNOS-S100A8/9 complex, NOS2 is involved in the selective S-nitrosylation of GAPDH and other targets, playing a significant role in inflammation by promoting the synthesis of IL6 and IL8.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted role of inducible Nitric oxide synthase in the body's response to inflammation and its involvement in tumoricidal and bactericidal actions could lead to innovative therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.